Kasper P. Kepp

Kongens Lyngby, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 109 publications

Restoring amyloid-β42 and γ-secretase function in Alzheimer's disease.

Restoring amyloid-β42 and γ-secretase function in Alzheimer's disease.

Journal: Brain : a journal of neurology

Published: May 23, 2025

Biases and debiasing in policy decision-making.

Biases and debiasing in policy decision-making.

Journal: European journal of clinical investigation

Published: February 17, 2025

Communicating scientific evidence: drugs for Alzheimer's disease as a case study.

Communicating scientific evidence: drugs for Alzheimer's disease as a case study.

Journal: Current medical research and opinion

Published: January 24, 2025

Response to "Variability of cognitive changes after donanemab treatment".

Response to "Variability of cognitive changes after donanemab treatment".

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: December 06, 2024

Comment on "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US".

Comment on "Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US".

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: December 06, 2024

COVID-19 advocacy bias in the BMJ: meta-research evaluation.

COVID-19 advocacy bias in the BMJ: meta-research evaluation.

Journal: BMJ open quality

Published: September 27, 2024

Zero-covid advocacy during the COVID-19 pandemic: a case study of views on Twitter/X.

Zero-covid advocacy during the COVID-19 pandemic: a case study of views on Twitter/X.

Journal: Monash bioethics review

Published: July 11, 2024

Excess mortality in Denmark, Finland, Norway and Sweden during the COVID-19 pandemic 2020-2022.

Excess mortality in Denmark, Finland, Norway and Sweden during the COVID-19 pandemic 2020-2022.

Journal: European journal of public health

Published: May 17, 2024

Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42.

Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42.

Journal: Journal of Alzheimer's disease : JAD

Published: May 03, 2024

Panel stacking is a threat to consensus statement validity.

Panel stacking is a threat to consensus statement validity.

Journal: Journal of clinical epidemiology

Published: April 25, 2024

Are lecanemab and donanemab disease-modifying therapies?

Are lecanemab and donanemab disease-modifying therapies?

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: April 22, 2024

Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit.

Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit.

Journal: Ageing research reviews

Published: April 10, 2024

Showing 1-12 of 109

Last Updated: 09/26/2026